FindTrial
Sign In

A retrospective analysis of patients with liver dysfunction received voriconazole for treatment fungal infections

A retrospective analysis of patients with liver dysfunction received voriconazole for treatment fungal infections

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RRC-17013951
Enrollment
Unknown
Registered
2017-12-15
Start date
2017-12-20
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fungal infection

Interventions

High risk group:Nil
Low risk group:Nil

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Aged more than 18 years; 2. Using of voriconazole for treatment or prevention fungal infections in patients with liver dysfunction; 3. at least one voriconazole plasma Cmin.

Exclusion criteria

Exclusion criteria: 1. simultaneous use of another antifungal agent; 2. combination of rifampicin,isoniazid,phenytoin and other potent CYP450 inducers and inhibitors; 3. lack of compliance with the recommended dosage regimen

Design outcomes

Primary

MeasureTime frame
Blood concentration;Clinical index;—

Countries

China

Contacts

Public ContactYan Miao

The Second Xiangya Hospital of Central South University?

yan.miao@126.com+86 13787783668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026